Decreased striatal D2 receptor binding in non-manifesting carriers of the DYT1 dystonia mutation

Neurology. 2005 Jan 25;64(2):347-9. doi: 10.1212/01.WNL.0000149764.34953.BF.

Abstract

To determine whether reduced striatal D2 receptor binding reported in patients with idiopathic torsion dystonia is associated with the genotype, the authors used PET and [11C]-raclopride to assess non-manifesting carriers of the DYT1 mutation. D2 receptor binding was reduced by approximately 15% in caudate and putamen (p < 0.005). These results suggest that striatal D2 binding reductions are a trait feature of the DYT1 genotype.

Publication types

  • Research Support, N.I.H., Extramural
  • Research Support, Non-U.S. Gov't
  • Research Support, U.S. Gov't, P.H.S.

MeSH terms

  • Adult
  • Aged
  • Carbon Radioisotopes / pharmacokinetics
  • Corpus Striatum / diagnostic imaging
  • Corpus Striatum / metabolism*
  • Dopamine Antagonists / pharmacokinetics
  • Dystonia Musculorum Deformans / genetics*
  • Female
  • Heterozygote
  • Humans
  • Imaging, Three-Dimensional
  • Male
  • Middle Aged
  • Molecular Chaperones / genetics*
  • Positron-Emission Tomography
  • Protein Binding
  • Raclopride / pharmacokinetics
  • Radiopharmaceuticals / pharmacokinetics
  • Receptors, Dopamine D2 / deficiency*
  • Receptors, Dopamine D2 / metabolism

Substances

  • Carbon Radioisotopes
  • Dopamine Antagonists
  • Molecular Chaperones
  • Radiopharmaceuticals
  • Receptors, Dopamine D2
  • TOR1A protein, human
  • Raclopride